TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Phio Pharmaceuticals ( (PHIO) ) just unveiled an update.
On November 3, 2025, Phio Pharmaceuticals announced agreements to exercise existing warrants for approximately 5.66 million shares of common stock, originally issued in 2024 and 2025, with exercise prices between $2.00 and $5.45 per share. The exercise of these warrants, expected to generate gross proceeds of about $13.4 million, will occur in multiple tranches, with initial closings on November 4 and 6, 2025, and additional closings by November 18, 2025. The proceeds will be used primarily for working capital and accelerating development activities for PH-762, a potential non-surgical treatment for skin cancers. H.C. Wainwright & Co. is serving as the exclusive placement agent for the offering.
The most recent analyst rating on (PHIO) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Phio Pharmaceuticals stock, see the PHIO Stock Forecast page.
Spark’s Take on PHIO Stock
According to Spark, TipRanks’ AI Analyst, PHIO is a Neutral.
Phio Pharmaceuticals is struggling financially, with no revenue and consistent losses, significantly impacting its stock score. The technical indicators show mixed signals, with some short-term momentum but bearish long-term trends. The valuation is speculative due to negative earnings. The recent board appointment is a positive corporate event but has limited impact on overall financial health.
To see Spark’s full report on PHIO stock, click here.
More about Phio Pharmaceuticals
Phio Pharmaceuticals Corp. is a clinical-stage siRNA biopharmaceutical company focused on developing therapeutics using its proprietary INTASYL® gene silencing technology aimed at enhancing the body’s immune cells to effectively target cancer cells. The company’s lead clinical program, PH-762, targets the PD-1 gene involved in various skin cancers, and is currently being evaluated in a Phase 1b trial for cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma.
Average Trading Volume: 2,710,198
Technical Sentiment Signal: Strong Sell
Current Market Cap: $9.33M
For a thorough assessment of PHIO stock, go to TipRanks’ Stock Analysis page.